1997
DOI: 10.1007/978-3-642-60377-8_135
|View full text |Cite
|
Sign up to set email alerts
|

High-Dose Chemotherapy with Busulfan, Cyclophosphamide, and VP-16 as Conditioning for Allogeneic and Autologous Bone Marrow Transplantation for Patients with Acute Myeloid Leukemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
26
0

Year Published

1999
1999
2014
2014

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 21 publications
(29 citation statements)
references
References 5 publications
3
26
0
Order By: Relevance
“…20 Etoposide with cyclophosphamide and Bu has been used in children with leukemias 7,21,22 and this combination was the subject of a pilot feasibility study by the Pediatric Blood and Marrow Transplant Consortium. 23 In the studies by Emminger, von Bueltzingsloewen, and the PBMTC, no unexpected toxicities were noted with the addition of etoposide, and the decision was made to include this drug to decrease relapses potentially.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…20 Etoposide with cyclophosphamide and Bu has been used in children with leukemias 7,21,22 and this combination was the subject of a pilot feasibility study by the Pediatric Blood and Marrow Transplant Consortium. 23 In the studies by Emminger, von Bueltzingsloewen, and the PBMTC, no unexpected toxicities were noted with the addition of etoposide, and the decision was made to include this drug to decrease relapses potentially.…”
Section: Discussionmentioning
confidence: 99%
“…However, the addition of etoposide has not been demonstrated to offer an advantage when added to Bu/cyclophosphamide in patients with leukemias in a prospective study. Studies in adults with leukemias and lymphomas have noted an increase in hepatotoxicity, including veno-occlusive disease (VOD), dermatologic toxicity, and mucositis, [22][23][24][25] without an increase in treatment-related mortality.…”
Section: Discussionmentioning
confidence: 99%
“…Twelve patients received conditioning regimens without TBI, consisting of busulfan (16 mg/kg) and cyclophosphamide and/or VP-16. 22,23 Supportive care…”
Section: Conditioning Regimensmentioning
confidence: 99%
“…High-dose therapy prior to autoSCT was Busulfan/Cyclophosphamide in three cases and BEAM, VIC and Busulfan/ Thiotepa in one case each [12]. Conditioning prior to allo-SCT was Busulfan/VP-16/Cyclophosphamide in five cases, Treosulfan/Fludarabine in three cases, and TBI/Fludarabine in two cases [13,14,15]. Busulfan/Fludarabine, Busulfan/ Cyclophosphamide, Melphalan/Fludarabine and Busulfan/ Melphalan/Fludarabine were given in one case each [16].…”
Section: Conditioning and Stem Cell Transplantationmentioning
confidence: 99%